PubMed (MeSH Keyword) for id: 122201352

Year	Number of Results
2011	1
2015	3
2016	5
2017	4
2018	5
2019	8
2020	18
2021	23
2022	17
2023	17
2024	5

1

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.

Qi Y, Li J, Lin S, Wu S, Chai K, Jiang X, Qian J, Jiang C. Qi Y, et al. Sci Rep. 2024 May 18;14(1):11388. doi: 10.1038/s41598-024-62356-w. Sci Rep. 2024. PMID: 38762672 Free PMC article.

2

Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET.

Xia S, Duan W, Xu M, Li M, Tang M, Wei S, Lin M, Li E, Liu W, Wang Q. Xia S, et al. J Exp Clin Cancer Res. 2024 Apr 3;43(1):103. doi: 10.1186/s13046-024-03015-w. J Exp Clin Cancer Res. 2024. PMID: 38570866 Free PMC article.

3

Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.

Vanderick A, Colinet B. Vanderick A, et al. Acta Clin Belg. 2024 Apr;79(2):148-151. doi: 10.1080/17843286.2024.2330137. Epub 2024 Mar 18. Acta Clin Belg. 2024. PMID: 38494868

4

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.

Ramesh S, Cifci A, Javeri S, Minne RL, Longhurst CA, Nickel KP, Kimple RJ, Baschnagel AM. Ramesh S, et al. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1379-1390. doi: 10.1016/j.ijrobp.2023.11.013. Epub 2023 Nov 16. Int J Radiat Oncol Biol Phys. 2024. PMID: 37979706

5

Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.

Chen MF, Harada G, Liu D, DeMatteo R, Falcon C, Wilhelm C, Kris MG, Drilon A, Gutgarts V. Chen MF, et al. J Thorac Oncol. 2024 Jan;19(1):153-159. doi: 10.1016/j.jtho.2023.09.1444. Epub 2023 Sep 23. J Thorac Oncol. 2024. PMID: 37748692

6

[Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].

Basse C, Régaldo-Saint Blancard L. Basse C, et al. Bull Cancer. 2023 Sep;110(9):869-871. doi: 10.1016/j.bulcan.2023.05.005. Epub 2023 Jul 11. Bull Cancer. 2023. PMID: 37442707 French. No abstract available.

7

Perfluoro-tert-butyl Group-Derived Capmatinib: Synthesis, Biological Evaluation and Its Application in ¹⁹ F Magnetic Resonance Imaging.

Zhang X, Wang L, Huang R, Wang J, Yan Q. Zhang X, et al. Chembiochem. 2023 Oct 4;24(19):e202300354. doi: 10.1002/cbic.202300354. Epub 2023 Aug 16. Chembiochem. 2023. PMID: 37345408

8

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Babey H, Jamme P, Curcio H, Assié JB, Veillon R, Doubre H, Pérol M, Guisier F, Huchot E, Decroisette C, Falchero L, Corre R, Cortot A, Chouaïd C, Descourt R. Babey H, et al. Target Oncol. 2023 Jul;18(4):585-591. doi: 10.1007/s11523-023-00976-4. Epub 2023 Jun 13. Target Oncol. 2023. PMID: 37310660

9

Severe hepatotoxicity during treatment with capmatinib.

Valencia Soto CM, Martínez Callejo V, García-Avello Fernández-Cueto A, Villacañas Palomares MV, Barbadillo Villanueva S, Ochagavía Sufrategui M, López-Brea Piqueras MF, Valero Domínguez M. Valencia Soto CM, et al. J Oncol Pharm Pract. 2023 Sep;29(6):1484-1488. doi: 10.1177/10781552231173120. Epub 2023 May 8. J Oncol Pharm Pract. 2023. PMID: 37157816

10

Capmatinib (Tabrecta) for NSCLC.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-e66. doi: 10.58347/tml.2023.1674d. Med Lett Drugs Ther. 2023. PMID: 37039616 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

85 results

Results by year